# Alzheimer's Disease Core Center

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2020 · $3,117,991

## Abstract

PROJECT SUMMARY: UNIVERSITY OF PENNSYLVANIA (PENN) ALZHEIMER'S DISEASE
(AD) CORE CENTER (ADCC) RENEWAL APPLICATION
ADCC Director and Principal Investigator (PI): John Q. Trojanowski, MD, PhD
ADCC Associate Directors: Jason Karlawish, MD and David Wolk, MD
 The Aims of the Penn ADCC are designed to achieve our mission of elucidating
mechanisms underlying AD by focusing on the spectrum of disease from earliest onset through
progressive stages of disease with the long term goal of accelerating the pace of developing
better diagnostics and preventions/treatments for AD and related disorders (RD). To this end,
the Specific Aims of this renewal application for the Penn ADCC are to: 1) oversee and direct
the activities of the ADCC (Administrative Core A); 2) recruit, follow and study patients with
AD, especially at their earliest stage, in addition to older cognitively normal subjects (CNs) with
a strong emphasis on African-Americans (Clinical Core B and Outreach and Recruitment
Core E); 3) provide data management, bioinformatics and biostatistical expertise for the
multimodal integration of clinical, imaging, biomarker, genetic and neuropathology data on AD,
as well as for cross-disease subtype comparisons bridging the entire spectrum of AD through
data integration, data analyses and bioinformatics (Data Management, Biostatistics and
Bioinformatics Core C); 4) establish postmortem diagnoses on ADCC patients, and bank AD
and RD CNS tissues, DNA and biofluids for diagnostic studies and research to understand AD
and RD pathophysiology, including mechanisms of disease progression, genetic factors
influencing heterogeneity of AD expression, and the emergence of diverse strains of misfolded
disease proteins (Neuropathology, Genetics and Biomarker Core D); 5) develop, implement,
and monitor outreach, recruitment and retention programs that provide the ADCC team, patients
and families, as well as our region with state-of-the-art knowledge about AD and associated co-
morbid conditions that influence risk for cognitive decline, while ensuring that our research
cohort reflects the ethnic and racial diversity of Penn's surrounding community (Outreach and
Recruitment Core E); 6) Continue our Pilot Grant Program to stimulate novel research across
the spectrum of AD and RD as well as normal aging through Core A which funds 2 pilots/year
and Penn's Institute on Aging (IOA), which funds an additional 4-6 pilots/year; 7) Continue
Collaborations with other investigators at and beyond Penn to improve understanding of and
diagnostics and treatments for AD as well as educate and empower the community. 8) Increase
our commitment since the launch of the Penn ADCC to train, mentor and nurture the next
generation of researchers on AD, RD and healthy brain aging by implementing the new
Research Education Component Core F. In summary, the Penn ADCC contributes to national
and global strategies to meet the worldwide challenges of rapidly aging populations and the
epidemic of AD an...

## Key facts

- **NIH application ID:** 9962201
- **Project number:** 5P30AG010124-30
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** JOHN Q. TROJANOWSKI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $3,117,991
- **Award type:** 5
- **Project period:** 1997-07-15 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9962201

## Citation

> US National Institutes of Health, RePORTER application 9962201, Alzheimer's Disease Core Center (5P30AG010124-30). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9962201. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*